ScoreWhy is Chengdu Easton Biopharmaceuticals Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 8.27% and Operating profit at 10.71% over the last 5 years
- RAW MATERIAL COST(Y) Fallen by -3.43% (YoY)
- DEBT-EQUITY RATIO (HY) Lowest at -47.74 %
2
With ROE of 7.78%, it has a fair valuation with a 3.67 Price to Book Value
- Over the past year, while the stock has generated a return of 61.97%, its profits have fallen by -4.7%
- At the current price, the company has a high dividend yield of 0.5
3
Market Beating Performance
- The stock has generated a return of 61.97% in the last 1 year, much higher than market (China Shanghai Composite) returns of 14.77%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Chengdu Easton Biopharmaceuticals Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Chengdu Easton Biopharmaceuticals Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Chengdu Easton Biopharmaceuticals Co., Ltd.
61.97%
0.77
56.57%
China Shanghai Composite
14.77%
1.01
14.58%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.27%
EBIT Growth (5y)
10.71%
EBIT to Interest (avg)
85.62
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.48
Sales to Capital Employed (avg)
0.42
Tax Ratio
4.69%
Dividend Payout Ratio
31.42%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.76%
ROE (avg)
8.84%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
47
Industry P/E
Price to Book Value
3.67
EV to EBIT
57.79
EV to EBITDA
37.38
EV to Capital Employed
6.21
EV to Sales
6.74
PEG Ratio
NA
Dividend Yield
0.51%
ROCE (Latest)
10.75%
ROE (Latest)
7.78%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend2What is working for the Company
RAW MATERIAL COST(Y)
Fallen by -3.43% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -47.74 %
-6What is not working for the Company
NET PROFIT(HY)
At CNY 77.04 MM has Grown at -25.81%
ROCE(HY)
Lowest at 8.31%
NET SALES(Q)
Lowest at CNY 301.46 MM
Here's what is working for Chengdu Easton Biopharmaceuticals Co., Ltd.
Debt-Equity Ratio
Lowest at -47.74 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by -3.43% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Chengdu Easton Biopharmaceuticals Co., Ltd.
Net Profit
At CNY 77.04 MM has Grown at -25.81%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (CNY MM)
Net Sales
Lowest at CNY 301.46 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Net Sales
At CNY 301.46 MM has Fallen at -9.25%
over average net sales of the previous four periods of CNY 332.19 MMMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
